Wells Fargo’s Grace Therapeutics GRCE Stock Holding History

Wells Fargo’s Portfolio GRCE Stock Details GRCE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$8.33K	Buy	+1,800	New	+$7.07K	﹤0.01%	6003
2020 Q1	–	Sell	-281	Closed	-$33K	–	6931
2019 Q4	$33K	Buy	+281	New	+$27.8K	﹤0.01%	5631
2019 Q3	–	Sell	-21	Closed	-$1K	–	6792
2019 Q2	$1K	Buy	+21	New	+$922	﹤0.01%	6299
2018 Q2	–	Sell	-180	Closed	-$9K	–	6627
2018 Q1	$9K	Hold	180	–	–	﹤0.01%	5975
2017 Q4	$8K	Buy	+180	New	+$12.1K	﹤0.01%	5978

Other funds holding GRCE

Cerity Partners New York $70.8B AUM 21.68% 1-Year Est. Return

Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

CCM

Connective Capital Management Palo Alto, California $121M AUM 39.82% 1-Year Est. Return

Wells Fargo's GRCE Position: Q1 2026 in Review

Wells Fargo opened a new position in Grace Therapeutics (GRCE) in Q1 2026: 1,800 shares worth $8.33K. The stake represents ﹤0.01% of the portfolio and ranks #6003 among its holdings. This is a return to the name: Wells Fargo previously reported a position in GRCE as recently as Q4 2019.

Wells Fargo first reported a position in GRCE in Q4 2017 and has held it in 5 quarters since. The position peaked at $33K in Q4 2019. 34 funds tracked by Wall St. Rank hold GRCE as of Q1 2026.

Wells Fargo held 1,800 shares of Grace Therapeutics worth $8.33K as of Q1 2026.
Grace Therapeutics was a new Wells Fargo position in Q1 2026.
Grace Therapeutics made up ﹤0.01% of Wells Fargo's portfolio in Q1 2026, its #6003 holding.
Wells Fargo first reported a position in Grace Therapeutics in Q4 2017 and has held it in 5 quarters since.
Wells Fargo's Grace Therapeutics position peaked at $33K in Q4 2019.
34 funds tracked by Wall St. Rank held Grace Therapeutics as of Q1 2026.

Based on Wells Fargo's 13F filing for Q1 2026, filed 11 May 2026.